UBS Initiates Prothena Corporation At Buy

Analysts at UBS initiated coverage on Prothena Corporation PLC PRTA with a Buy rating. The target price for Prothena Corporation is set to $58. Prothena Corporation shares have gained 92.11 percent over the past 52 weeks, while the S&P 500 index has surged 9.48 percent in the same period. Prothena Corporation shares closed at $39.44 in pre-market trading.